

Juan G. Abraldes

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8819036/juan-g-abraldes-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

12,107
citations

58
h-index

109
g-index

148
ext. papers

14,658
ext. citations

6.9
avg, IF

6.24
L-index

#	Paper	IF	Citations
137	Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. <i>Hepatology</i> , 2017 , 65, 310-335	11.2	936
136	Early use of TIPS in patients with cirrhosis and variceal bleeding. <i>New England Journal of Medicine</i> , 2010 , 362, 2370-9	59.2	802
135	The clinical use of HVPG measurements in chronic liver disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009 , 6, 573-82	24.2	441
134	Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. <i>Gastroenterology</i> , 2004 , 126, 469-75	13.3	386
133	Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. <i>Hepatology</i> , 2003 , 37, 902-8	11.2	366
132	Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. <i>Gastroenterology</i> , 2013 , 144, 102-111.e1	13.3	336
131	Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 776-83	6.9	336
130	Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. <i>Hepatology</i> , 2008 , 48, 442-8	11.2	292
129	Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. <i>Gastroenterology</i> , 2009 , 136, 1651-8	13.3	288
128	A histologic scoring system for prognosis of patients with alcoholic hepatitis. <i>Gastroenterology</i> , 2014 , 146, 1231-9.e1-6	13.3	254
127	Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. <i>Journal of Hepatology</i> , 2008 , 48, 229-36	13.4	231
126	Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. <i>Journal of Hepatology</i> , 2013 , 58, 45-50	13.4	209
125	Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. <i>Gastroenterology</i> , 2004 , 126, 749-55	13.3	208
124	Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients. <i>Hepatology</i> , 2013 , 58, 1824-35	11.2	203
123	A new scoring system for prognostic stratification of patients with alcoholic hepatitis. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2747-56	0.7	200
122	Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. <i>American Journal of Gastroenterology</i> , 2006 , 101, 506-12	0.7	200
121	The management of portal hypertension: rational basis, available treatments and future options. <i>Journal of Hepatology</i> , 2008 , 48 Suppl 1, S68-92	13.4	191

120	Current management of portal hypertension. <i>Journal of Hepatology</i> , 2003 , 38 Suppl 1, S54-68	13.4	188
119	A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. <i>Gastroenterology</i> , 2014 , 146, 412-19.e3	13.3	183
118	Good long-term outcome of Budd-Chiari syndrome with a step-wise management. <i>Hepatology</i> , 2013 , 57, 1962-8	11.2	180
117	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology</i> , 2016 , 150, 1160-1170.e3 ¹⁷¹	13.3	171
116	Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. <i>Journal of Hepatology</i> , 2007 , 46, 1040-6	13.4	169
115	β-blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2019 , 393, 1597-1608	4.0	160
114	Measurement of portal pressure and its role in the management of chronic liver disease. <i>Seminars in Liver Disease</i> , 2006 , 26, 348-62	7.3	160
113	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. <i>Hepatology</i> , 2015 , 62, 762-72	11.2	159
112	Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. <i>Journal of Clinical Investigation</i> , 2012 , 122, 368-82	15.9	150
111	Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. <i>Hepatology</i> , 2010 , 52, 2044-52	11.2	143
110	Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. <i>Clinical Gastroenterology and Hepatology</i> , 2008 , 6, 1412-7	6.9	142
109	Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, G980-7	5.1	138
108	Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. <i>PLoS ONE</i> , 2012 , 7, e32785	3.7	136
107	Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. <i>Journal of Hepatology</i> , 2010 , 53, 558-67	13.4	132
106	Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1920-6.e2	6.9	131
105	KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins. <i>Gut</i> , 2015 , 64, 1434-43	19.2	115
104	Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. <i>Journal of Hepatology</i> , 2012 , 56, 103-8	13.4	114
103	Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. <i>Hepatology</i> , 2003 , 37, 172-81	11.2	110

102	A Model to Identify Sarcopenia in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1473-1480.e3	6.9	108
101	Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1159-67	0.7	103
100	Portal hypertension: from bedside to bench. <i>Journal of Clinical Gastroenterology</i> , 2005 , 39, S125-30	3	103
99	Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. <i>Gut</i> , 2011 , 60, 1133-8	19.2	102
98	A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale. <i>American Journal of Gastroenterology</i> , 2016 , 111, 1759-1767	0.7	102
97	Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. <i>Journal of Hepatology</i> , 2009 , 51, 279-87	13.4	101
96	Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension. <i>Hepatology</i> , 2006 , 43, 485-91	11.2	93
95	Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. <i>PLoS ONE</i> , 2013 , 8, e58742	3.7	92
94	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018 , 154, 1694-1705.e4	13.3	90
93	Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. <i>Journal of Hepatology</i> , 2010 , 52, 846-53	13.4	90
92	Portal hypertension and gastrointestinal bleeding. <i>Seminars in Liver Disease</i> , 2008 , 28, 3-25	7.3	86
91	Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. <i>Digestive and Liver Disease</i> , 2012 , 44, 855-60	3.3	85
90	Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2010 , 53, 273-82	13.4	85
89	Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. <i>Hepatology</i> , 2002 , 36, 1367-73	11.2	84
88	Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. <i>Hepatology</i> , 2010 , 52, 1783-90	11.2	70
87	Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. <i>Hepatology</i> , 2003 , 37, 378-84	11.2	68
86	Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction. <i>Hepatology</i> , 2013 , 57, 1172-81	11.2	66
85	Somatostatin and analogues in portal hypertension. <i>Hepatology</i> , 2002 , 35, 1305-12	11.2	66

84	Portal cholangiopathy: radiological classification and natural history. <i>Gut</i> , 2011 , 60, 853-60	19.2	65
83	Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 296, G147-56	5.1	65
82	Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. <i>Journal of Hepatology</i> , 2003 , 39, 515-21	13.4	61
81	Home Exercise Training Improves Exercise Capacity in Cirrhosis Patients: Role of Exercise Adherence. <i>Scientific Reports</i> , 2018 , 8, 99	4.9	58
80	Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. <i>Liver Transplantation</i> , 2010 , 16, 348-56	4.5	58
79	Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study. <i>Hepatology</i> , 2010 , 51, 2108-16	11.2	57
78	Insulin resistance and liver microcirculation in a rat model of early NAFLD. <i>Journal of Hepatology</i> , 2011 , 55, 1095-102	13.4	54
77	Characterization of T cell subsets in organ transplantation. <i>Transplant International</i> , 2010 , 23, 1045-55	3	54
76	Acute variceal bleeding. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012 , 33, 46-54	3.9	53
75	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020 , 73, 1082-1091	13.4	52
74	Liver cirrhosis. <i>Lancet, The</i> , 2021 , 398, 1359-1376	40	50
73	Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids. <i>Liver International</i> , 2019 , 39, 1437-1447	7.9	47
72	Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. <i>Journal of Hepatology</i> , 2013 , 58, 1140-6	13.4	47
71	Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2012 , 96, 584-90	7	43
70	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 31-41	18.8	43
69	The treatment of acute variceal bleeding. <i>Journal of Clinical Gastroenterology</i> , 2007 , 41 Suppl 3, S312-7	3	39
68	Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. <i>Journal of Hepatology</i> , 2006 , 44, 886-93	13.4	39
67	Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. <i>Liver International</i> , 2014 , 34, 16-25	7.9	38

66	Utility of color Doppler ultrasonography predicting tips dysfunction. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2696-701	0.7	38
65	Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. <i>Journal of Hepatology</i> , 2011 , 55, 307-14	13.4	36
64	Impact of Implementing a "FIB-4 First" Strategy on a Pathway for Patients With NAFLD Referred From Primary Care. <i>Hepatology Communications</i> , 2019 , 3, 1322-1333	6	33
63	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. <i>Hepatology</i> , 2013 , 58, 2079-88	11.2	33
62	Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. <i>Hepatology</i> , 2006 , 43, 27-33	11.2	33
61	Cirrhosis as new indication for statins. <i>Gut</i> , 2020 , 69, 953-962	19.2	32
60	Complications after ERCP in liver transplant recipients. <i>Gastrointestinal Endoscopy</i> , 2011 , 74, 285-94	5.2	31
59	Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 72-8	6.9	29
58	Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 1125-33	5.6	28
57	Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. <i>Hepatology</i> , 2019 , 69, 1287-1299	11.2	28
56	Diagnosing and monitoring cirrhosis: Liver biopsy, hepatic venous pressure gradient and elastography. <i>Gastroenterología Y Hepatología</i> , 2012 , 35, 488-95	0.9	27
55	Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. <i>Hepatology</i> , 2006 , 43, 34-41	11.2	26
54	Portal hypertension secondary to myelofibrosis: a study of three cases. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2355-8	0.7	26
53	Molecular profiling of subclinical inflammatory lesions in long-term surviving adult liver transplant recipients. <i>Journal of Hepatology</i> , 2018 , 69, 626-634	13.4	25
52	The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1472-80	0.7	25
51	Nitric oxide and portal hypertension. <i>Metabolic Brain Disease</i> , 2002 , 17, 311-24	3.9	25
50	Patients whose first episode of bleeding occurs while taking a β -blocker have high long-term risks of rebleeding and death. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 670-6; quiz e58	6.9	23
49	Extrahepatic portal vein thrombosis in children and adolescents: Influence of genetic thrombophilic disorders. <i>World Journal of Gastroenterology</i> , 2010 , 16, 6123-7	5.6	23

48	The management of portal hypertension. <i>Clinics in Liver Disease</i> , 2005 , 9, 685-713, vii	4.6	23
47	Non-invasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. <i>Disease Markers</i> , 2011 , 31, 129-38	3.2	22
46	Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation. <i>Shock</i> , 2017 , 47, 370-377	3.4	21
45	Metabolomics discloses potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension. <i>American Journal of Gastroenterology</i> , 2013 , 108, 926-32	0.7	21
44	Spleen stiffness: toward a noninvasive portal sphygmomanometer?. <i>Hepatology</i> , 2013 , 57, 1278-80	11.2	21
43	Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis. <i>American Journal of Gastroenterology</i> , 2013 , 108, 75-82	0.7	20
42	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021 , 74, 1660-1673	11.2	20
41	The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis. <i>Current Treatment Options in Gastroenterology</i> , 2018 , 16, 226-240	2.5	19
40	Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. <i>British Journal of Haematology</i> , 2004 , 124, 329-35	4.5	19
39	Management of gastrointestinal bleeding in patients with cirrhosis of the liver. <i>Seminars in Hematology</i> , 2004 , 41, 8-12	4	19
38	Insulin resistance in patients with cirrhosis and portal hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2012 , 302, G1458-65	5.1	18
37	Impact of obesity and insulin-resistance on cirrhosis and portal hypertension. <i>Gastroenterology & Hepatology</i> , 2013 , 36, 527-33	0.9	17
36	Variceal bleeding: pharmacological therapy. <i>Digestive Diseases</i> , 2005 , 23, 18-29	3.2	17
35	Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. <i>Journal of Hepatology</i> , 2013 , 59, 717-22	13.4	16
34	Lactate and number of organ failures predict intensive care unit mortality in patients with acute-on-chronic liver failure. <i>Liver International</i> , 2019 , 39, 1271-1280	7.9	15
33	Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2013 , 305, G496-502	5.1	15
32	Developments and controversies in the management of oesophageal and gastric varices. <i>Gut</i> , 2010 , 59, 701-5	19.2	15
31	A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures. <i>Liver International</i> , 2015 , 35, 695-703	7.9	14

30	A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding. <i>Hepatology</i> , 2020 , 72, 1353-1365	11.2	14
29	Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd-Chiari patients. <i>Liver Transplantation</i> , 2001 , 7, 649-51	4.5	14
28	Patient-perceived barriers to lifestyle interventions in cirrhosis. <i>Saudi Journal of Gastroenterology</i> , 2017 , 23, 97-104	3	14
27	A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients. <i>American Journal of Gastroenterology</i> , 2010 , 105, 1917-21	0.7	11
26	Bacterial infections in acute variceal hemorrhage despite antibiotics-a multicenter study of predictors and clinical impact. <i>United European Gastroenterology Journal</i> , 2017 , 5, 1090-1099	5.3	8
25	Selective arterial embolization for life threatening hemobilia after transjugular intrahepatic portosystemic shunt placement. <i>Journal of Hepatology</i> , 2001 , 34, 174-6	13.4	8
24	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021 , 74, 200-219	13.4	8
23	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study. <i>Liver Transplantation</i> , 2013 , 19, 450-6	4.5	7
22	Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis. <i>Hepatology</i> , 2020 , 72, 1029-1042	11.2	7
21	The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. <i>Journal of Hepatology</i> , 2021 , 75 Suppl 1, S118-S134	13.4	7
20	Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis. <i>Liver International</i> , 2008 , 28, 566-73	7.9	6
19	Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension. <i>Journal of Hepatology</i> , 2006 , 44, 1040-5	13.4	6
18	Statins: the Panacea of Cirrhosis?. <i>Current Hepatology Reports</i> , 2016 , 15, 1-7	1	5
17	Decreased intrahepatic response to alpha(1)-adrenergic agonists in lipopolysaccharide-treated rats is located in the sinusoidal area and depends on Kupffer cell function. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007 , 22, 893-900	4	5
16	Novel approaches to treat portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002 , 17 Suppl 3, S232-41	4	3
15	A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. <i>BMC Gastroenterology</i> , 2021 , 21, 120	3	3
14	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. <i>Journal of Hepatology</i> , 2021 , 75, 1026-1033	13.4	3
13	Lack of correlation between preoperative and intraoperative liver hemodynamics: a descriptive analysis. <i>Transplantation</i> , 2014 , 97, 116-21	1.8	2

12	Can We Add the History of the Nonoperative Therapy of Varices to Other Success Chapters of Modern Medicine?. <i>Clinical Liver Disease</i> , 2020 , 16, 73-82	2.2	1
11	Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?. <i>Journal of Hepatology</i> , 2021 , 75, 750-752	13.4	1
10	Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list.. <i>Hepatology Communications</i> , 2022 ,	6	1
9	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH).. <i>Liver International</i> , 2022 ,	7.9	1
8	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis.. <i>Hepatology Communications</i> , 2021 ,	6	1
7	Royal Free Hospital-estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis. <i>Liver International</i> , 2021 , 41, 819-827	7.9	0
6	Non-invasive alloimmune risk stratification of long-term liver transplant recipients. <i>Journal of Hepatology</i> , 2021 , 75, 1409-1419	13.4	0
5	Reply. <i>Gastroenterology</i> , 2016 , 151, 1037-1038	13.3	
4	Management of Portal Hypertension 2017 , 304-335		
3	Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 2017-21	5.6	
2	An uncommon cause of massive scrotal enlargement. <i>Liver International</i> , 2010 , 30, 995	7.9	
1	Issues in Trial Design and Areas Needing Further Research 2016 , 355-363		